- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-502/11: Judgment of the General Court of 17 May 2013 — Sanofi Pasteur MSD v OHIM — Mundipharma (Representation of two devices of crossing sickles) (Community trade mark — Opposition proceedings — Application for Community figurative mark representing two devices of crossing sickles — Earlier national and international figurative marks representing two devices of ribbons — Relative ground for refusal — No likelihood of confusion — Article 8(1)(b) of Regulation No 207/2009)
ECLI:EU:UNKNOWN:62011TA0502
62011TA0502
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
29.6.2013
Official Journal of the European Union
C 189/21
(Case T-502/11)(1)
(Community trade mark - Opposition proceedings - Application for Community figurative mark representing two devices of crossing sickles - Earlier national and international figurative marks representing two devices of ribbons - Relative ground for refusal - No likelihood of confusion - Article 8(1)(b) of Regulation No 207/2009)
2013/C 189/41
Language of the case: German
Parties
Applicant: Sanofi Pasteur MSD SNC (Lyon, France) (represented by: T. de Haan, P. Péters and V. Wellens, lawyers)
Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: G. Schneider, acting as Agent)
Other party to the proceedings before the Board of Appeal of OHIM: Mundipharma AG (Basel, Switzerland) (represented by: F. Nielsen, lawyer)
Re:
Action brought against the decision of the Fourth Board of Appeal of OHIM of 22 July 2011 (Case R 1904/2010-4), relating to opposition proceedings between Sanofi Pasteur MSD SNC and Mundipharma AG
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Sanofi Pasteur MSD SNC to pay the costs.
OJ C 340, 19.11.2011.